Jade Biosciences (JBIO) Insider Mark Eisner Buys 47,675 Shares

On June 25, 2026, insider Mark Eisner purchased 47,675 shares of Jade Biosciences, Inc. (NasdaqCM: JBIO). The stock was trading at about $21.81 on that Saturday. This transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Jade Biosciences, Inc.

Eisner's purchase is part of a series of recent insider transactions. On June 9, 2026, several insiders, including Erin Lavelle and Lawrence Otto Klein, each bought 34,843 shares. These transactions were also not under Rule 10b5-1 plans.

Other Institutional Activity in Jade Biosciences

Several institutional investors have also adjusted their positions in Jade Biosciences. FMR LLC grew its holdings by 190,935 shares to a total of 7,085,423 shares, valued at approximately $99.55 million, marking a 2.8% increase. Bellevue Group AG added 160,399 shares, increasing its stake by 4.8% to 3,501,502 shares worth about $49.20 million. Meanwhile, Janus Henderson Group PLC opened a new position with 3,105,669 shares valued at $43.56 million.

Jade Biosciences, Inc. Stock Up 29.9%

As of Saturday, shares of Jade Biosciences were trading near $21.81. The company has a market capitalization of around $1.33 billion. Its stock has experienced a 52-week low of $6.67 and a high of $28.00. The biotech firm has a 50-day moving average of $21.44 and a 200-day moving average of $14.93. Jade Biosciences maintains a strong liquidity position with a current ratio of 14.29 and a quick ratio of 13.96, while its debt-to-equity ratio stands at 0.29.

Analysts Set New Price Targets

Analysts remain optimistic about Jade Biosciences. On June 15, 2026, UBS initiated coverage with a 'buy' rating and a price target of $45. Earlier in June, Wedbush and BTIG maintained their 'buy' ratings with targets of $45 and $74, respectively. Overall, the consensus recommendation is a 'strong buy' with a mean price target of $48.50, based on eight analyst opinions.

About Jade Biosciences, Inc.

Jade Biosciences, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing therapies for inflammation and immunology, particularly for autoimmune diseases. The company is working on JADE101, a monoclonal antibody in phase 1 clinical trial, along with other preclinical projects. Led by CEO Tom Frohlich, Jade Biosciences collaborates with Paragon Therapeutics and employs 55 people.

Bottom Line

Mark Eisner's recent share purchase highlights ongoing insider interest in Jade Biosciences, Inc. The company's focus on innovative therapies in the biotech sector, coupled with its strong liquidity and positive analyst sentiment, makes it a stock to watch. As always, it's important to remember that insider transactions are just one piece of the puzzle and may not reflect current market conditions.